tetano
Editor, Senior Moderator
Infection
. 2021 Oct 8.
doi: 10.1007/s15010-021-01710-w. Online ahead of print.
Coronavirus disease 2019 and peripheral blood eosinophil counts: a retrospective study
Marjella Eijmael[SUP] 1 [/SUP], Nicky Janssens[SUP] 2 [/SUP], Saskia le Cessie[SUP] 3 [/SUP], Yordi van Dooren[SUP] 4 [/SUP], Ted Koster[SUP] 2 [/SUP], Faiz Karim[SUP] 2 [/SUP]
Affiliations
Abstract
Purpose: Eosinopenia has been described in COVID-19. With this study, we aim to study the peripheral blood eosinophil counts in COVID-19 patients and to investigate whether there is an association between the peripheral blood eosinophil counts and disease severity of COVID-19.
Methods: We revised the electronical medical records of confirmed COVID-19 patients with polymerase chain reaction (PCR) assays in the Groene Hart Ziekenhuis, Gouda, The Netherlands. We divided patients in mild, moderate and severe groups based on clinical severity of COVID-19. Clinical severity was based on the therapy needed and the outcome of patients. We compared clinical characteristics, laboratory results and outcome between the three groups.
Results: Of the 230 patients included in this study, the mild, moderate and severe groups consisted of 16.5%, 45.7% and 37.8% of the included patients, respectively. The mean age was 68 years (IQR 57-78). 63% of patients were male. A significant decrease in the peripheral eosinophil counts was found corresponding to the increase of COVID-19 severity. In the mild, moderate and severe groups, the percentage of patients with eosinopenia was 73.7%, 86.7% and 94.3%, respectively (p value 0.002).
Conclusion: Eosinopenia is significantly more frequent present in patients with a severe COVID-19.
Keywords: COVID-19 disease; Complete blood count; Eosinopenia; Lymphopenia; Peripheral blood eosinophil count; SARS-CoV2.
. 2021 Oct 8.
doi: 10.1007/s15010-021-01710-w. Online ahead of print.
Coronavirus disease 2019 and peripheral blood eosinophil counts: a retrospective study
Marjella Eijmael[SUP] 1 [/SUP], Nicky Janssens[SUP] 2 [/SUP], Saskia le Cessie[SUP] 3 [/SUP], Yordi van Dooren[SUP] 4 [/SUP], Ted Koster[SUP] 2 [/SUP], Faiz Karim[SUP] 2 [/SUP]
Affiliations
- PMID: 34625911
- DOI: 10.1007/s15010-021-01710-w
Abstract
Purpose: Eosinopenia has been described in COVID-19. With this study, we aim to study the peripheral blood eosinophil counts in COVID-19 patients and to investigate whether there is an association between the peripheral blood eosinophil counts and disease severity of COVID-19.
Methods: We revised the electronical medical records of confirmed COVID-19 patients with polymerase chain reaction (PCR) assays in the Groene Hart Ziekenhuis, Gouda, The Netherlands. We divided patients in mild, moderate and severe groups based on clinical severity of COVID-19. Clinical severity was based on the therapy needed and the outcome of patients. We compared clinical characteristics, laboratory results and outcome between the three groups.
Results: Of the 230 patients included in this study, the mild, moderate and severe groups consisted of 16.5%, 45.7% and 37.8% of the included patients, respectively. The mean age was 68 years (IQR 57-78). 63% of patients were male. A significant decrease in the peripheral eosinophil counts was found corresponding to the increase of COVID-19 severity. In the mild, moderate and severe groups, the percentage of patients with eosinopenia was 73.7%, 86.7% and 94.3%, respectively (p value 0.002).
Conclusion: Eosinopenia is significantly more frequent present in patients with a severe COVID-19.
Keywords: COVID-19 disease; Complete blood count; Eosinopenia; Lymphopenia; Peripheral blood eosinophil count; SARS-CoV2.